Federica Ferrario (@Fefe_Ferrario) header
Federica Ferrario (@Fefe_Ferrario) profile picture

Radiation Oncologist ☢️ focused on GU 🌰 and lung 🫁 cancers @ Fondazione IRCCS San Gerardo dei Tintori - Authenticity is my superpower ✨

Saronno, Lombardia
Joined June 2021
Photo by Federica Ferrario (@Fefe_Ferrario)Photo by Federica Ferrario (@Fefe_Ferrario)Photo by Federica Ferrario (@Fefe_Ferrario)Photo by Federica Ferrario (@Fefe_Ferrario)Photo by Federica Ferrario (@Fefe_Ferrario)Photo by Federica Ferrario (@Fefe_Ferrario)Photo by Federica Ferrario (@Fefe_Ferrario)Photo by Federica Ferrario (@Fefe_Ferrario)Photo by Federica Ferrario (@Fefe_Ferrario)Photo by Federica Ferrario (@Fefe_Ferrario)
So proud to share mid-term results of our POPART trial on prostate bed SBRT — core of my thesis and a project I deeply believe in ✨ Alongside #SCIMITAR & #SHORTER, another step towards the 5fx revolution! 💥 Forever🙏🏼@StAr_MCM74 50days free access⬇️ authors.elsevier.com/c/1lYbQ…
9
27
3
84
10,407
Federica Ferrario retweeted
🚀 Update on single-fx 24 Gy SBRT+ADT for UIR & selected HR #PCa: ✅ encouraging PROs with low AEs ✅ 💯% BRFS 🎯Baseline IPSS and bladder trigone D1cc 🔗 to ⬆️GU AES 💥One day. Ablative. Promising Full PRO analysis now out 👇 authors.elsevier.com/c/1o7hN… #SBRT #ProstateCancer
1
8
26
2,355
A memorable #EMUC26 in Brussels🇧🇪 Proud to present in a stellar Game Changers session, with my husband special guest in the audience❤️ Great moments with friends and inspiring scientific discussions, including sharing our work with @matteo_mom64240🎯 #RadOnc @ESTRO_RT @Uroweb
3
44
2,330
Federica Ferrario retweeted
💥 shortening treatment for PCa: promising data that 3️⃣-fraction SBRT with real time TPUS works well! #prostate #SBRT @Cancers_MDPI
🏷️ 3-fraction #prostate #SBRT with real-time TPUS guidance was feasible, with uncommon severe GU/GI AEs, preserved QoL, and encouraging early biochemical control across all risk groups. Longer follow-up and prospective comparison are warranted. Unlock 🔓mdpi.com/2072-6694/18/18/295…
3
14
821
Federica Ferrario retweeted
Across 3 prospective studies, the signal for post-prostatectomy SBRT in 5 fx is increasingly consistent: feasible, low toxicity & excellent in-field control. StereoBed randomized data show no PRO/toxicity penalty; POPART/esSBRT show few local failures. #ASTRO26 @rtdess @HimanshuNagarMD @RadOncDocJ @NRGonc @ASTRO_org @urotoday @ChadTangMD @TylerSbrt @SbrtSean @jryckman3 @seanmmcbride
2
33
1
72
4,331
So proud of our #POPART around the 🌍 superbly presented by @PanizzaDenis 👏🏼 @StAr_MCM74 @valefacc22 @CChissotti @CiroFranzese1 @Raffa_Lucchini @roberta_muni
Post-prostatectomy RT in just 5 fractions? 👀 Ferrario et al and POPART team reports 100 pts treated with prostate-bed SBRT (32.5 Gy/5 fx): • Late ≥G2 GU toxicity: 8.5% • Only 1 late G2 GI event • Just 3 in-field relapses • 30-mo biochemical control: 74% Very encouraging local control and toxicity—but urinary QoL remains important to watch. #ASTRO26 #ProstateCancer #SBRT @HimanshuNagarMD @rtdess @RadOncDocJ @angela_jia_ @urotoday @TylerSbrt
4
6
25
1,512
Federica Ferrario retweeted
Virtually walking the halls at #ASTRO2026 as a medical oncologist, I keep coming back to the same thought: radiation oncology is quietly rewriting what “definitive local therapy” can look like. The unveiling of Accela from @SiemensHealthineers is more than another linac. Single-breath-hold SBRT, multi-site treatments in ~60 seconds, imaging-to-beam-off in under 90 seconds. Speed that actually changes biology and logistics, not just throughput. Patients spend less time on the table. Targets have less chance to move. Adaptive workflows become practical rather than aspirational. What strikes me most as a simple.medonc is the accumulating evidence that SBRT is matching surgery in more and more settings: early lung cancer, localized prostate (PACE-A data here this week), selected oligometastases, small HCC. Every time we add a tumor type to that list, we spare someone anesthesia, a wound, weeks of recovery, and the cascade of complications that still follow even “minimally invasive” operations. Surgery will always have its place. But the risk-benefit conversation is shifting. For older, frail, or multi-morbid patients, the ones I see every clinic day, the non-invasive option is no longer a consolation prize. It is often the more thoughtful one. The field is not just getting more precise. It is getting faster, smarter, and more humane. That is worth paying attention to, even from the medical oncology side of the hallway. Well done my fellow radoncs!!
2
26
1
94
6,190
🚨 New publication! 3-fx SBRT (30Gy) with real-time US tracking for localized #PCa: safe, well tolerated, low severe side effects, preserved QoL & encouraging early BRFS results (98.2% at 12mo) Huge congrats 👏🏼 @matteo_mom64240 & Ilenia on their 1️⃣paper! mdpi.com/2072-6694/18/18/295…
1
9
28
1,323
Amici radio‑oncologi👋🏼 con i colleghi del Gruppo GU AIRO, abbiamo preparato una survey sulla recidiva biochimica post-prostatectomia, per arrivare a pillole pratiche condivise su necessità reali💊🎯 ⏳Servono solo 5 minuti surveymonkey.com/r/Recidiva-… #PCa #bcr #RadOnc #survey
2
4
14
672
Congratulations Prof @StAr_MCM74 ranked #1🌍 for publication output in hypofractionated radiotherapy for prostate cancer 👏🏻 A great recognition of years of dedication to clinical practice and research in this field Proud to be part of the journey! 🥂 📄pmc.ncbi.nlm.nih.gov/article…
1
15
775
Federica Ferrario retweeted
10 Must-Read Posts in GU Oncology This Week | Second Week of July This week’s selection covers: • FDA approval of perioperative EV + pembrolizumab in MIBC, based on KEYNOTE-905/EV-303 • Treatment timing and NAC in MIBC • ARTO and TRAP: SABR/MDT in mCRPC • PACE-B: late urinary toxicity after prostate SBRT • CHAI biomarker, developed in CHAARTED and validated in ENZAMET, for treatment intensification in mHSPC • Practical guidance for [177Lu]Lu-PSMA-617 in mCRPC • Tumor-informed ctDNA monitoring during EV ± pembrolizumab in advanced urothelial carcinoma • VEGF/PD-1 bispecifics in RCC • Molecular features of hyperprogressive disease during anti-PD-1/PD-L1 immunotherapy • Endoscopic kidney-sparing surgery in upper tract urothelial carcinoma @Fefe_Ferrario @PiccoliniAndrea @DrAndrewLoblaw @ChrisSweens1 @neerajaiims @DrPaulNguyen @CaPsurvivorship @charlesryanmd @umangtalking @drenriquegrande @brian_rini @Pietro9609 @a_bravob @ugogradilone @tompowles1 Read more on @oncodaily - oncodaily.com/genitourinary-… #GUOncology #OncoDaily
6
8
371
⏳ New editorial out on late GU SE after #PCa SBRT in PACE-B trial ⚡️ Congrats to @DrMedo58935306 on leading this insightful collaboration. Curious? 📖 Read it for the clinical takeaways tau.amegroups.org/article/vi… @banu_atalar @alison_tree @nickva1 @EmmaHall71 @DrAndrewLoblaw
9
33
2,464
New paper out!🎉 📄Progression-directed ablative RT improves EFS in #oligoprogressive #NSCLC 87👥 with PDRT 📊1-yr EFS: 52.1% ⏱️Median TTNT: 8mo ✅Better if: PDRT on primary; #CR before oligopro PDRT: a real option to delay systemic therapy change💪🏼 🔗lnkd.in/d597bc_R
4
2
35
1,428
Federica Ferrario retweeted
Less could be better? Great presentation and results by @Fefe_Ferrario SBRT in 3fx for PC #ESTRO26
8
17
892
What a day at #ESTRO26 in Stockholm! 🙌🏼 ✅ Two poster discussions on #PCa ✅ Discussant for #OligoCare in the Lancet-Green Journal Top Trials plenary ✅ Bonus interview with @AIRO80327989 🎙️ Real science, real passion 💙 #RadiationOncology #SBRT #ProstaceCancer #Oligometastatic
4
20
1,236
Federica Ferrario retweeted
📣 #ESTRO26 - @UmbertoRicardo e2irradiate @EORTC prospective OLIGOCARE registry of SABR for oligomets. ~2500 patients, ~3500 mets. ➡️ local failure 5% at 1 year and 11% at 3 years ➡️ Colorectal cancer has higher risk of progression ➡️ minimum PTV dose correlated with outcome We should aim to deliver high quality SABR to optimise control! #radonc
2
51
4
103
11,587
Federica Ferrario retweeted
Interesting read! All radical treatments for pca have toxicities. The key issue for pts is not simply if toxicity occurs, but which toxicities persist and how they affect long-term QOL. Transient GU symptoms are not equivalent to permanent incontinence or impotence
This quoted post is unavailable.
3
11
1
41
14,517
Great energy🔋at the #AdvancedUroOncologyDays! Congrats to the organizers @mat_sepu @therealmarcodoc @PorrecaAngelo for 2️⃣superb days. 🙏🏼for this brilliant educational event Proud to have presented on #bcr and salvage treatment personalization 🎤💙 #UroOnc #RadOnc #ProstateCancer
2
6
227
Excited to join #AdvancedUroOncologyDays2026 tomorrow at IOV! 🎯 Ready to tackle a challenging topic with leading specialists ✨ See you there! 🔬 #UroOncology #RadiationOncology
Domani 📆 16–17 aprile | Castelfranco Veneto Advanced Uro-Oncology Days 2026 Le neoplasie urologiche richiedono oggi un approccio sempre più integrato, capace di unire competenze, tecnologie e strategie terapeutiche in continua evoluzione. Dalla malattia renale a quella uroteliale e prostatica, il confronto tra specialisti si concentra sull’applicazione concreta delle evidenze più recenti e sull’integrazione tra chirurgia, radioterapia e terapie sistemiche. Due giornate dedicate alla condivisione di esperienze, alla discussione tra pari e alla costruzione di percorsi sempre più personalizzati nella pratica clinica. Responsabili Scientifici: Marco Maruzzo @therealmarcodoc, Angelo Porreca, Matteo Sepulcri @mat_sepu. ➡️ Guarda il programma: overgroup.eu/evento/advanced… @alongi_filippo, @Antonioamodeo79, @aleantonellibs1, @StAr_MCM74, @ALESSIOBRUNI10, @NBuffi, @Sebastiano_Buti, @OrnellaCampane1, @AlessandroCres @BElkhouzai, @lauraevangelis9, @Fefe_Ferrario, @Frances15466778, @LuigiFormisano_, @Raffa_Lucchini, @GLughezzani, @MaioranoBrigida, @andreamari08, @fmassari79, @MatroneFabio, @saramerler, @NicosiaMd, @CParonetto, @RebuzziSara, @mimma_rizzo, @Giandoroviello, @SScagliarini_, @RSchiavina, @MariaChiaraMCS, @IsmaelaVas96. #UroOncology #Oncologia #Multidisciplinarietà #PrecisionMedicine #Innovazione #ECM #MedicalEducation
9
289
Federica Ferrario retweeted
🔍Check out a post-hoc analysis of the ABRUPT trial on the 🔗between ☢️ RT dose to pelvic substructures & late GU TOX ⛔️ bladder trigone D1cc ≥20.3 Gy ⛔️ NVB D0.035 cc ≥23.6 Gy ➡️doi.org/10.1016/j.ctro.2026.… #prostatecancer @OncoAlert @oncodaily @urotoday
2
7
17
1,387
Federica Ferrario retweeted
🙏 Huge credit to all speakers, moderators and colleagues who made the 1️⃣#prostateSBRTMonza 🇮🇹Symposium a great success🤩 #ProstateCancer @ESTRO_RT @ISRSy @airo_young
6
26
1,256